Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Use of Intravenous Busulphan for Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT) Is Associated with Delayed T-Cell Full Donor Chimerism and Lower Incidence of Acute Graft Versus Host Disease.

ZiYi Lim, Murugaiyan Thanigaikumar, Shreyans Gandhi, Laurence Pearce, Michelle Kenyon, Aloysius Y.L. Ho, Stephen Devereux, Antonio Pagliuca, Ghulam J. Mufti

Blood (2007) 110 (11): 1994.

https://doi.org/10.1182/blood.V110.11.1994.1994

Published: 2007

Journal Articles

Fanconi-Like Syndrome with Negative Chromosomal Breakages Test and High Incidence of Myelodysplasia.

Sunil Gupta, MD, Saad M.B. Rassam, MD, Madan Riyali, MD, Aloysius Y.L. Ho, MD, Ghulam Mufti, MD

Blood (2007) 110 (11): 1681.

https://doi.org/10.1182/blood.V110.11.1681.1681

Published: 2007

Journal Articles

Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine.

ZiYi Lim, Aloysius Y.L. Ho, Jonathon Samuel, Janet Hayden, Guillermo Garcia-Manero, Ghulam J. Mufti

Blood (2007) 110 (11): 1449.

https://doi.org/10.1182/blood.V110.11.1449.1449

Published: 2007

Journal Articles

Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation.

M. Mansour Ceesay, MRCPath, ZiYi Lim, MRCPath, Michelle Kenyon, Aloysius Y.L. Ho, FRCPath, Stephen Devereux, FRCPath, Steve Schey, FRCPath, Aleksandar Mijovic, FRCPath, Antonio Pagliuca, FRCPath, Ghulam J. Mufti, FRCPath

Blood (2007) 110 (11): 1665.

https://doi.org/10.1182/blood.V110.11.1665.1665

Published: 2007

Journal Articles

Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

Wendy Ingram, MD, Zi Y. Lim, MD, Michelle Kenyon, RN, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Y.L. Ho, MD, Mufti Ghulam, MD

Blood (2006) 108 (11): 3108.

https://doi.org/10.1182/blood.V108.11.3108.3108

Published: 2006

Journal Articles

The Pattern of T-Cell Donor Chimerism Is a Key Predictor of Outcome Following Alemtuzumab Based Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for MDS and AML.

ZiYi Lim, Laurence Pearce, Aloysius Y.L. Ho, Linda Barber, Wendy Ingram, Monica Usai, Stephen Devereux, Antonio Pagliuca, Ghulam Mufti

Blood (2006) 108 (11): 42.

https://doi.org/10.1182/blood.V108.11.42.42

Published: 2006

Journal Articles

Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate.

Dragana Milojkovic, MD, Satyajit Sahu, MD, Jeffery Henderson, MD, Barbara H. Czepulkowski, John R. Salisbury, MD, William T. Bellamy, MD, Stephen Devereux, MD, Antonio Pagliuca, MD, Aloysius Y.L. Ho, MD, Ghulam J. Mufti, MD

Blood (2004) 104 (11): 1999.

https://doi.org/10.1182/blood.V104.11.1999.1999

Published: 2004

Journal Articles

Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT).

Aloysius Y.L. Ho, MD, Sujal R. Desai, MD, Ian D.P. Stanton, MD, Susan J. Copley, MD, Athol U. Wells, MD, Antonio Pagliuca, MD, Stephen Devereux, MD, Ghulam J. Mufti, MD

Blood (2004) 104 (11): 1831.

https://doi.org/10.1182/blood.V104.11.1831.1831

Published: 2004

Journal Articles

Analysis of Beam (Carmustine, Etoposide, Cytosine Arabinoside, Melphalan) Versus High Dose Melphalan (HDM) with Autologous Rescue in Multiple Myeloma(MM).

Karthikeyan A. Ramasamy, Ruth Branford, Radha Selvaratnam, Aloysius Y.L. Ho, Rafael Duarte, Stephen Devereux, Antonio Pagliuca, Ghulam Mufti

Blood (2004) 104 (11): 5227.

https://doi.org/10.1182/blood.V104.11.5227.5227

Published: 2004

NARROW

Use of Intravenous Busulphan for Reduced Intensity Conditioning (RIC) Haematopoietic Stem Cell Transplantation (HSCT) Is Associated with Delayed T-Cell Full Donor Chimerism and Lower Incidence of Acute Graft Versus Host Disease.

Fanconi-Like Syndrome with Negative Chromosomal Breakages Test and High Incidence of Myelodysplasia.

Outcomes of MDS Patients with Chromosome 7 Abnormalities Treated with 5-Azacytidine.

Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation.

Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).

The Pattern of T-Cell Donor Chimerism Is a Key Predictor of Outcome Following Alemtuzumab Based Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for MDS and AML.

Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate.

Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT).

Analysis of Beam (Carmustine, Etoposide, Cytosine Arabinoside, Melphalan) Versus High Dose Melphalan (HDM) with Autologous Rescue in Multiple Myeloma(MM).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only